The clinical effect of paravalvular leak (PVL) following circumferentially sutured surgical cardiac valve replacement varies significantly depending on the type of valve prosthesis and the implant location. Because the long-term outcomes of this complication, as well as surgical or transcatheter interventions for PVL, are largely unknown, there is a fundamental need for these studies. The absence of comprehensive retrospective or prospective data arises from the lack of uniform definitions to establish disease severity, clinical endpoints to assess safety and efficacy, and appropriate single and composite endpoints to assess outcomes. In addition, cohort/statistical considerations may be specific to this disease process.
Following publication of the first standardized definitions and endpoints associated with cardiac valvular operations, 1,2 the Valve Academic Research Consortium (VARC) has collaborated with the U.S. Food and Drug Administration and device manufacturers to periodically update consensus definitions for clinical endpoints in valve implantation. Accordingly, the Paravalvular Leak Academic Research Consortium (PVLARC) working group harnessed Academic Research Consortium (ARC) methodologies and assembled to discuss current knowledge and evidence concerning clinical studies of PVL therapies. Representatives from the U.S. Food and Drug Administration, device manufacturers, and academic research organizations in the United States and Europe joined a panel of clinical cardiologists, interventional cardiovascular specialists, imaging experts, cardiovascular surgeons, and regulatory and clinical trial experts at the American College of Cardiology Heart House in February 2015 to review and summarize the current state of knowledge on surgical PVL. As a result of this effort, this document provides consensus expert opinion on core principles and endpoint definitions for clinical studies of PVL (Central Illustration). This document focuses exclusively on PVL following valve replacement with circumferentially sutured surgical prosthetic valves, defined as an abnormal communication between the sewing ring of a surgical prosthesis and the native annulus. PVL related to transcatheter valve prostheses is comprehensively discussed in the VARC-2, Mitral Valve Academic Research Consortium, and various reviews. 3, 4 The Online Appendix discusses unanswered questions related to this intervention, which could form the basis for clinical studies.
Core Principles I: Clinical
PVLs of varying clinical significance are detected in 5% to 18% of all implanted surgical valves, with an incidence of 2% to 10% in the aortic position and 7% to 17% in the mitral position. [5] [6] [7] Risk factors for PVL development include: annular calcification, tissue friability, prior endocarditis, or other inflammatory processes and recent initiation of corticosteroid therapy. [8] [9] [10] [11] Multiple procedural factors may increase the risk of PVL: implantation type (mechanical implants are a greater risk than bioprosthetic implants), position (supra-annular prostheses are a greater risk than annular aortic prostheses), and surgical technique (continuous sutures are a greater risk than interrupted sutures for mitral prostheses). 6, 7 A majority (74%) of PVL occurs within the first year of valve implantation. 12 Late PVL is commonly related to suture dehiscence associated with infective endocarditis or the gradual resorption of annular calcifications that are not completely debrided. 13 Figure 1 summarizes the prevalence and etiology of PVL. Percutaneous PVL repair offers an alternative to traditional surgery, especially for patients who are considered to be at high surgical risk.
14 Two large single-center studies involving 57 and 141 patients with PVL, respectively, reported overall success rates for percutaneous PVL of 77% to 86.5% , and clinical success ranging from 67% to 77%. 15, 16 A recent Bayesian meta-analysis, using cardiac mortality as a 0.40) . Following PVL closure, improvement in heart failure (HF) symptoms is typically limited to patients with no or mild residual regurgitation. 18 Patients with hemolytic anemia may not improve following PVL closure. Hein et al. 19 observed that 33% of patients with transfusion-requiring hemolysis had worsening hemolysis after transcatheter-attempted closure, and there was newly developed hemolysis in 10% of all patients. Persistent hemolytic anemia after attempted PVL closure predicts poor survival and need for cardiac surgery. 20 A recent singlesite study of the effect of changes in procedural technique, use of advanced imaging modalities (i.e., 3-dimensional [3D] echocardiography), and device choice (smaller nitinol braided devices) on outcomes showed a significant learning curve effect on procedure and fluoroscopy time, complications (30-day major adverse cardiovascular events), and hospital length of stay. 21 The predominant mechanism of device failure in this study was bioprosthetic leaflet impingement, highlighting the need for defect-specific devices.
The current American College of Cardiology (ACC)/American Heart Association (AHA) indications for percutaneous PVL repair include patients with prosthetic valves and symptomatic HF (NYHA functional class III to IV) and persistent hemolytic anemia, who have anatomic features that are suitable for percutaneous surgery in centers of expertise. 14 Closure of less-severe PVL remains controversial. Percutaneous repair is contraindicated in patients with active endocarditis or significant dehiscence involving more than one-fourth to one-third of the valve ring. 22 
Clinical presentation and risk assessment of PVL
Approximately 2% to 5% of PVL are clinically relevant, and are associated with complications of congestive HF, hemolytic anemia, and infective endocarditis. 5, 11, 23 Most PVLs are small and asymptomatic;
however, approximately 90% of patients with symptomatic leaks typically present with congestive HF, 13, 22 which can be precipitated or worsened by anemia. 13 Hemolytic anemia resulting from shear stress on the red blood cells is the second most common presentation of PVL, affecting one-third to three-quarters of patients with symptomatic PVL. 8, 13 Symptoms of anemia can be severe and may require transfusion, and patients may experience poor quality of life (QOL). 24, 25 PVL can also increase the risk for infectious endocarditis. 26 Mortality rates of 7% to 11% have been observed in contemporary single-site studies among those undergoing surgical reoperation for PVL, 27, 28 and reports of perioperative complications (e.g., infection, stroke, and myocardial infarction) appear higher for surgical repair than for percutaneous closure. 29 However, a direct comparison of closure techniques has never been performed. Surgical risk may be especially high in patients with PVL who are severely symptomatic and have significant comorbidities, 8 or in whom dehiscence involves a substantial portion of the sewing ring. 30 After attempted transcatheter PVL closure, residual leak of moderate degree or more is associated with a higher risk of need for cardiac surgery or of death. 18 The Society of Thoracic Surgeons risk score and the EuroSCORE II system are widely used for surgical risk evaluation in cardiac surgery; however, such scores have been validated only in standard 
surgical-risk patients, 3 and they may fail to adequately capture risk factors for patients undergoing PVL closure. These factors must be considered by the heart team when deciding on the appropriateness of intervening. Table 1 outlines the recommended evaluation of patients before PVL closure. Online Table 1 summarizes the studies supporting the clinical data and pre-procedural work-up before PVL closure. Online Table 2 summarizes the studies supporting the proposed post-procedural evaluation.
Current guidelines suggest an initial transthoracic echocardiogram (TTE) be performed 6 weeks to 3 months after valve implantation to assess the effects of surgery and to serve as a baseline for comparison. 14 For bioprosthetic valves, routine echocardiographic surveillance is considered appropriate > _3 years after implantation if there is no known or suspected valve dysfunction. 31 It is the opinion of the writing group that after the initial baseline post-operative evaluation, which would include imaging and laboratory testing, yearly follow-up is necessary to better characterize the true prevalence of PVL and its consequences, such as hemolysis. After PVL closure, yearly follow-up assessment is also indicated to determine continued safety and efficacy. A comprehensive evaluation would include clinical and functional assessment (i.e., with echocardiography), as well as laboratory evaluation of hemolysis. The role of routine assessment of biomarkers has not been studied.
Core Principles II: Diagnostic Testing for Assessment of Location and Severity of PVL
A variety of diagnostic tests should be performed to determine whether regurgitation following prosthetic valve replacement is functional or abnormal and, if abnormal, whether it is central or paravalvular and the regurgitant severity. Echocardiography is the diagnostic test of choice for assessment of prosthetic valve function; however, several imaging modalities, each with its own individual merits ( Table 2) , can be used to assess the spatial and anatomic dimensions of PVL in surgical prosthetic valves 14, 32 (Online Table 3 ).
Echocardiography
Echocardiography is the imaging modality of choice for the comprehensive evaluation of surgical valve function, left and right heart chamber size and function, and pulmonary artery pressures. 14, 32, 33 Echocardiographic assessment of qualitative and quantitative measures in PVL requires an integrative process utilizing 2-dimensional (2D), 3D, and Doppler echocardiographic modalities, as well as TTE and transesophageal echocardiography (TEE). [33] [34] [35] TTE provides a superior assessment of transvalvular gradients, chamber sizes, and function compared with TEE. TEE is ideal for mechanistic evaluation of prosthetic valve regurgitation, and is superior to TTE for imaging of mitral prosthetic valve regurgitation. However, TEE requires conscious sedation or anesthesia and is expert-driven, both for quality of image acquisition and interpretation. 36 Prosthetic material causes numerous ultrasound artifacts that may reduce diagnostic sensitivity. 33 For the evaluation of aortic valve prostheses, both modalities may be required because acoustic shadowing prevents imaging of the posterior sewing ring from TTE parasternal long-axis images and the anterior sewing ring from TEE midesophageal views. Like TTE, TEE is less reliable for prognostic evaluation of PVL in the intermediate range, 37 with considerable overlap of mild and moderate PVL. Although the first-line diagnostic test is 2D echocardiography, 3D echocardiography plays a significant role in determining the precise location and size of the PVL. In addition, 3D TEE is an essential tool for intraprocedural guidance. Limitations of 3D TEE remain: artifacts of ultrasound imaging (i.e., echocardiographic dropout, acoustic shadowing, and reverberation artifacts), and reduced temporal and spatial resolution. 35 Multibeat acquisitions that stitch together smaller subvolumes will allow for visualization of larger regions of the heart with higher temporal and spatial resolution, but with the loss of real-time imaging (the subvolumes are created by sequential RR cycles) and the creation of stitching (or reconstruction) artifacts when subvolumes are not precisely aligned. 38 Echocardiographic assessment parameters for PVL Assessing prosthetic structural parameters The initial assessment of PVL includes an evaluation of prosthetic valve structural integrity. Sewing ring stability and motion, or any abnormal space between the sewing ring and native annulus, may be the first indication of PVL. For the mitral prosthesis, native annular deformation or retained native leaflets may result in the appearance of increased valve mobility. On echocardiography (as well as cinefluoroscopy), significant dehiscence is suggested by excessive rocking motion of the mitral prosthesis >15 compared with the annulus. 36 For the aortic prosthesis, motion is restricted by the smaller aortic space; thus, motion discordant with the motion of the adjacent aortic root and native annulus usually indicates significant (40% to 90% of the annular circumference) dehiscence. 39 Grading of paravalvular regurgitation Accurate echocardiographic assessment of prosthetic valve regurgitation should include an assessment of the location (central versus paravalvular) and quantification of regurgitant severity. Assessment of PVL can be challenging and requires an integrative approach. 33 Although guidelines, consensus statements, and studies have used both a 3-class grading scheme (mild, moderate, severe) and the angiographic 4-class scheme to report the severity of prosthetic regurgitation, these schemes have many pitfalls, and intermediate grades may not be reliably estimated. 40, 41 A unifying 5-class scheme for PVL regurgitation severity following transcatheter AVR has recently been proposed to improve communication between members of the heart team, resolve differences between grading schemes, and align echocardiographic parameters with clinically-used terminology, and is recommended by the writing group for clinical trials. 42 The proposed 5-class schemes for aortic (Table 3 ) and mitral ( Table 4 PVL provide a mechanism for systematic study of PVL outcomes, and a means for correlating outcomes with prior grading schemes. Importantly, this proposed grading scheme is not intended to replace existing guidelines, but could be used as the initial grading scheme and then collapsed into the 3-class scheme for reporting and/or outcomes analysis. A suggested hierarchy of parameters is summarized in Figure 2 for prosthetic aortic PVL and Figure 3 for prosthetic mitral PVL. A recent multicenter study using cardiac magnetic resonance (CMR) to quantify PVL following transcatheter aortic valve replacement used regurgitant fraction cutoffs recommended by the VARC-2 criteria: none/trace (RF < _ 15%), mild (16% to 29%), and moderate/ severe (> _30%). 43 By ROC analysis, a regurgitant fraction of > _ 30%
best identified patients at greatest risk for 2-year mortality and the composite of mortality and rehospitalization for HF. These results, together with the echocardiographic outcomes from the PARTNER II SAPIEN 3 trial, using the granular grading scheme showing increased mortality associated with moderate or greater PVL 44 not only help validate the cutoffs for PVL severity in Table 3 , but also support the use of the unifying grading scheme nomenclature. 42 
Color Doppler
For both mitral and aortic prosthetic regurgitation, qualitative color Doppler features are the primary mode used for assessing PVL • Estimate of PA pressure • Limited utility for paravalvular regurgitation *After Lancellotti et al. 60 and Nishimura et al.
†
Structural deterioration defined as: dysfunction or deterioration intrinsic to the valve, including calcification, leaflet tear, or flail. Nonstructural deterioration, defined as abnormalities not intrinsic to the valve itself, including suture dehiscence with associated paravalvular regurgitation, problems related to retained native mitral apparatus, prosthesispatient mismatch, or pannus formation. ‡ By planimetry or phase-contrast. 69 2D, 2-dimensional; 3D, 3-dimensional; CMR, cardiac magnetic resonance; CT, computed tomography; LA, left atrium; LV, left ventricle; PA, pulmonary artery; PHV, prosthetic heart valve; RV,right ventricle; TEE, transesophageal echocardiography; TR, tricuspid regurgitation; TTE, transthoracic echocardiography. Parameters that are less often applicable due to pitfalls in the feasibility/accuracy of the measurements or to the interaction with other factors. §
For bileaflet mechanical valve, E velocity >1.9 m/s is abnormal.
| PHT should not be used to calculate valve area in the setting of a prosthetic valve; however, it should be normal in the absence of significant stenosis. ¶
Care must be taken to avoid over gaining or incomplete spectral traces (i.e., when the jet moves in and out of the Doppler beam).
# Pulmonary vein flow reversal may be influenced by LV systolic and diastolic function, LA size and pressure, atrial arrhythmias, and the presence of mitral inflow obstruction; however, holosystolic flow reversal is specific for severe mitral regurgitation. **Regurgitant volume is calculated as the difference of stroke volume measured in the LV outflow tract minus 2D-derived (total) LV stroke volume. 
PVL-ARC Endpoint Definitions
by the sewing ring and adjacent native structures. Importantly, jet length and area should not be used to quantify aortic regurgitation. 33, 46 For mitral prosthetic PVL, vena contracta width and downstream jet size are more difficult to assess; however, the presence of proximal flow convergence is a useful TTE color Doppler parameter that would initiate further evaluation by TEE. Circumferential extent of the jet can be used to grade severity of PVL, with extensive involvement (> _25% to 30%) a possible indication for surgical repair instead of a transcatheter approach.
Pulsed and continuous wave Doppler
For aortic prosthetic PVL evaluation, other parameters of jet density and pressure halftime of the regurgitant jet can be qualitative or semiquantitative supportive measures of PVL severity. The timing and velocity of the diastolic flow reversal in the descending aorta is a further Doppler parameter that can also corroborate PVL severity. 42 These parameters are unreliable indicators of AR severity, given their dependence on blood pressure and aortic and ventricular compliance.
For mitral prosthetic PVL, signs of significant increase in flow across the valve (increased mean gradients and high transmitral flow compared with left ventricular outflow tract [LVOT] flow) in the setting of a normal pressure halftime, can be used to indicate prosthetic valve dysfunction secondary to regurgitation. Systolic reversal of pulmonary vein flow is a specific sign of significant regurgitation, unless a narrow jet is directed into the vein. The absence of systolic reversal after intervention is important supportive evidence of successful treatment.
Quantitative Doppler echocardiography
High transvalvular velocities or gradients with parameters suggestive of a normal valve area are the initial clues to increased transvalvular flow and possible nonphysiological regurgitation. Pulsed wave and continuous wave Doppler should be used to evaluate relative stroke volumes across both the LVOT and right ventricular outflow tract, and thus quantify the aortic regurgitant volume, regurgitant fraction, and effective regurgitant orifice area. 33 Quantifying diastolic stroke volume across the prosthetic mitral valve is limited by flow acceleration at the level of the sewing ring. The 2D-derived left ventricular (LV) stroke volume can be used to quantify regurgitant volume by subtracting the Doppler-derived stroke volume from a nonregurgitant valve. Using 3D-derived LV stroke volume may increase the accuracy of this method; however, it systematically underestimates volumes compared with CMR.
47,48
Direct planimetry of vena contracta area Offline analysis of 3D color Doppler volumes can be used to planimeter the PVL vena contracta area and accurately measure the dimensions of the regurgitant jet, with a 3D color regurgitant orifice major diameter> _0.65 cm consistent with greater than moderate PVL. 49 Outcomes based on these parameters will require further study.
Sizing paravalvular regurgitation defects
The exact location and size of the defects help determine the optimal approach (transseptal, transapical, or retrograde aortic) and the type and/or size of the device. Measurements of PVL include: 1) precise location of the defect(s); 2) precise radial and circumferential dimensions of the defects, as well as the vena contracta area; 3) orientation of the defect in relation to the sewing ring and prosthetic valve occluders or leaflets; and 4) location and orientation of subvalvular structures. Although 2D imaging may accurately locate defects and measure radial dimensions, the circumferential extent of the defect is best imaged with 3D TEE. 50 Similarly, the regurgitant orifice area can be planimetered on noncolor 3D images; 51 however, confirmation by both 2D and 3D color Doppler imaging should be performed to exclude an artifact of imaging. In addition, direct measurement of the color Doppler vena contracta area and dimensions by 3D volumes correlates better with standard measures of regurgitant severity compared with noncolor 3D imaging, 49 and thus may be superior for localizing and sizing the regurgitant jets, especially when contemplating transcatheter closure.
52
3D TEE is also integral to intraprocedural guidance, and may be especially beneficial in evaluating the success of percutaneous closure of mitral PVL. 53, 54 The real-time 3D volume of the mitral sewing ring should be positioned in the surgical view with the aortic valve at the top of the mitral ring (12 o'clock) and the left atrial appendage (LAA) at approximately the 9-o'clock position. 35, 55 Careful 2D and 3D
imaging throughout the procedure is required to confirm: 1) catheter and device positioning; 2) full deployment of the device in the intended position; 3) interference of the device with prosthetic valve function or adjacent native anatomy; 4) stable device deployment; 5) residual regurgitation and need for further intervention; and 6) safe removal of catheters and imaging of transseptal shunt. Echocardiographic-fluoroscopic fusion imaging allows real-time overlay of 2D, 3D, or color Doppler images onto the fluoroscopic image, and thus has the potential to improve procedural guidance by rapid localization of PVL defects, and improving communication between the imager and interventionalist. 56 Intracardiac echocardiography has also been used for intraprocedural guidance. 57 Other measures of cardiac structure and function Important clinical information can be gleaned from assessing ventricular and atrial size and function. This is especially important for mitral regurgitation; however, pre-existing abnormalities of chamber size and function should be considered when interpreting changes in these parameters following surgical valve replacement. LV diameters from M-mode or 2D imaging, as well as left atrial (LA) volumes (preferably by biplane Simpson's method) should be measured with chronic severe regurgitation resulting in severe dilation of both the LV and LA.
In the setting of symptomatic, severe mitral PVL, an increase in estimated pulmonary artery pressures (tricuspid regurgitation velocity >3 m/s, systolic pulmonary artery pressure> _50 mm Hg), with resulting right atrial and ventricular dilation, is also seen. For the aortic prosthesis, current guidelines recommend followup assessment of the aortic root and ascending aorta. 33 Measurement of LV size and function should be performed, because chronic severe aortic PVL should result in dilation of the LV similar to native aortic regurgitation (AR).
14 Finally, echocardiographic imaging may detect cavitation bubbles, which are frequently seen with normal prosthetic valve function. 58 A large number of bubbles may be an indication of hemolysis and be correlated with levels of lactate dehydrogenase (LDH). 59 
Nonechocardiographic imaging modalities
Cinefluoroscopy and cineangiography Cinefluoroscopy is a noninvasive, readily-available method for detecting and evaluating mechanical occluder motion when prosthetic valve stenosis is suspected; [60] [61] [62] however, this modality has limited utility for the diagnosis of PVL location and severity, unless significant dehiscence results in excessive motion of the sewing ring.
Retrograde cineangiography for the assessment of regurgitation has relied on the semiquantitative grading scheme of Sellers et al. 63 Biplane techniques may increase the accuracy of angiographic grading. 64 A number of factors confound reliable quantification, resulting in inconsistent correlation with quantitative assessment of AR and significant overlap between angiographic grades. 40, 41 Finally, angiography cannot elucidate the location or mechanism of PVL, and the writing group considers this a confirmatory method to distinguish less than mild from greater than moderate regurgitation. Intraprocedurally, retrograde cineangiography may be useful to assess for adequate aortic prosthetic PVL closure, particularly when the defects are in the anterior sewing ring, and thus are poorlyimaged by TEE.
Cardiac computed tomographic assessment of PVL
A recent meta-analysis of multimodality imaging for prosthetic valve dysfunction concluded that computed tomography (CT) allowed adequate assessment of most modern prosthetic heart valves, complementing echocardiographic detection of the etiology of valve obstruction (pannus/thrombus or calcifications) and endocarditis extent (valve dehiscence and pseudoaneurysm), without a clear advantage over echocardiography for the detection of vegetations or periprosthetic regurgitation. 61 CT can provide images with improved spatial resolution, which allow for anatomic evaluation of PVL location and can be used to plan interventions. 12, 15 A recent study showed that CT and 2D TEE had similar diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy) in the detection of PVL. 65 CT has significant limitations for PVL assessment: it cannot display blood flow, requires iodinated contrast media and ionizing radiation, and requires expertise in CT post-processing/reconstruction. Nonetheless, CT is especially strong at anatomically characterizing an area of valvular dehiscence and resultant PVL, especially in the setting of mechanical valves with significant shadowing during sonographic assessment. CT can identify leak location and size of defect, tract trajectory, calcification within the track and adjacent annular tissue, as well as important surrounding cardiac structures, and define the optimal fluoroscopic angles to cross the defect. 57 The PVLARC recommends that CT angiography be performed before consideration for reoperation. Fusion hybrid imaging is also being increasingly integrated into clinical practice. 66 With proper gating and multiplanar imaging, CT with fusion imaging can determine the location of PVL, its path and surrounding structures, and the fluoroscopic angles for wiring and catheter cannulation. 67 3D printing of CT data is also increasingly feasible, 68 facilitating the understanding of the defect.
CMR imaging for assessment of prosthetic valve function
Studies have shown the feasibility and accuracy of CMR for the assessment of prosthetic valve function. 69 Quantitation of regurgitation can be performed by planimetry of the anatomic regurgitant orifice area from the cine CMR acquisitions of the valve, 70, 71 quantification of forward and backward flow, 72 and phase-contrast imaging. 61 Phase-contrast velocity mapping (also known as velocity-encoded cine or Q flow) has become the primary mode for assessing regurgitant volume by CMR, and provides information on prosthetic flow patterns and velocities for the visual detection of prosthetic regurgitation. For this purpose, phasecontrast imaging is obtained in a short-axis plane cutting the aorta just above the prosthetic valve to measure the antegrade and retrograde aortic flows, and then to calculate the regurgitant volume and fraction. 73 The accuracy of CMR to grade PVL may be altered by arrhythmias, as well as flow turbulences and signal void in the vicinity of the prosthetic valve (especially mechanical valves). Moreover, because the coronary artery diastolic flow is included in the final regurgitant volume assessment, CMR may lead to a slight overestimation of AR, and does not allow precise separation among mild, trace, and no AR. Nonetheless, CMR can been used to not only quantify PVL following transcatheter aortic valve replacement, but also predict outcomes. 43 CMR may be particularly useful for corroborating the severity of regurgitation in cases where echocardiography remains inconclusive, and/or when there is discordance between the echocardiographic grading of PVL severity and the patient's symptomatic status and/or degree of LV dilation/dysfunction. The advantages of CMR for PVL assessment include the capacity to measure regurgitant volumes for multiple valve types, irrespective of regurgitant jet number or morphology, 74 and high reproducibility of measurements. 75 Further outcome studies related to CMR grading of surgically-placed prostheses are urgently needed to confirm the cutpoint values of CMR regurgitant volume and fraction that should be used to grade the severity of chronic PVL.
Nuclear studies
Because implantation of transcatheter devices is contraindicated in the setting of active endocarditis, nuclear studies, such as labeledleukocyte scintigraphy 76 and positron emission tomography (PET) with 18 F-fluorodeoxyglucose, may help with the diagnosis of endocarditis in the setting of prosthetic valves. 77 18 F-fluorodeoxyglucose PET/CT and PET/CT angiography may improve the diagnostic accuracy of the modified Duke Criteria 78 in patients with suspected infective endocarditis and prosthetic valves. 79 Invasive hemodynamic assessment of PVL Hemodynamic measurements have also been proposed as a means of quantifying the severity of regurgitation. Although elevated filling pressures reflect the hemodynamic consequences of regurgitation, and thus indicate clinical compromise, there are limitations to invasive hemodynamic assessment. There is poor correlation between AR severity and aortic pressure at end-diastole and pulse pressure. 80, 81 The dicrotic notch on the downstroke of the arterial pressure waveform is thought to represent slight backward flow in the aorta on closure of the aortic valve; absence of the dicrotic notch is associated with severe AR, but cannot be used to define lesser grades. Grading of AR using hemodynamic tracings has been validated using measurement of the "corrected" diastolic pulse pressure (between the dicrotic notch and enddiastole) or the diastolic slope (slope of the pressure drop following the dicrotic notch), 82 with a direct relationship between these measurements and larger regurgitant volumes. An AR index was recently proposed to assess intraprocedural regurgitation during transcatheter aortic valve implantation, 83 but has not been validated in the setting of chronic PVL following surgical valve implantation. Hemodynamic assessment in the setting of severe mitral regurgitation is typically limited to the nonspecific measurement of right heart pressures and pulmonary capillary wedge pressure, as well as indirect evidence of regurgitant flow. 84 Direct LA pressure measurements or assessment of LA to LV pressure gradients are rarely warranted. Neither method can delineate the mechanism of valvular insufficiency.
Nonimaging assessment
Blood biomarkers of PVL Recent studies suggest that the high-molecular-weight von Willebrand factor multimeric pattern may be used as a sensor of PVL following valve procedure. 85, 86 A platelet function analyzer that measures the time for platelet aggregation to occlude a collagen and adenosine diphosphate (ADP)-coated membrane (closure time with ADP), is a point-of-care assay that is very sensitive to high-molecularweight multimer changes. Investigators have shown that CT closure time with ADP could be used to monitor in real-time valve hemodynamic performance after transcatheter valve replacement, and has prognostic utility. 86 The turbulent flow caused by the leak around the prosthetic valve is presumed to generate excessive shearing forces on red blood cells, resulting in intravascular mechanical hemolysis. 24 Factors that increase shear stress, such as important pressure fluctuations during strenuous physical activity, may aggravate the hemolysis. Hemodialysis and the heart-lung bypass machine are other causes of mechanical hemolytic anemia that can be seen in patients with significant PLV. Iron or folate deficiency may further alter the erythrocyte membrane and favor hemolysis. Specific laboratory studies may help confirm the presence of hemolytic anemia. A hemoglobin or hematocrit is an obvious first step, but significant hemolysis may still be present despite a normal or near-normal hemoglobin/hematocrit count if the bone marrow is capable of compensating for the peripheral red blood cell destruction. In such an instance, the calculation of a reticulocyte production index (or corrected reticulocyte count) may help refine the diagnosis. 87 The hemolysis workup should also include serum LDH, haptoglobin, iron and folic acid levels, and peripheral blood smear examination for schistocytes. Consultation with a hematologist is strongly advised. A summary of the approach to diagnostic testing is shown in Figure 4 . 
Core Principles III: Clinical Trial Design Definitions of clinical success for PVL trials
The following are definitions of success for PVL closure.
Technical success (on exit from procedure laboratory)
Absence of procedural mortality or stroke; Successful access, delivery, and retrieval of the device delivery system; Proper placement and positioning device(s); Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and Continued intended safety and performance of the device, including: a. No evidence of structural or functional failure of the prosthetic valve b. No specific device-related technical failure issues and complications c. Reduction of regurgitation to no greater than mild (1þ) paravalvular regurgitation (and without associated hemolysis).
Device success (30-day and all other post-procedural intervals)
Absence of procedural mortality or stroke; Original intended device(s) in place;
Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and Continued intended safety and intended performance of the device: a. Structural performance: no migration, embolization, detachment, fracture, worsening of hemolysis, or systemic emboli related to device thrombosis or endocarditis, among others; b. Hemodynamic performance: persistent reduction in paravalvular insufficiency without producing central valvular incompetence or stenosis; and c. Absence of para-device complications (e.g., erosion of bioprosthetic leaflet or surrounding tissue, LVOT, or valvular gradient increase >10 mm Hg)
Procedural success (30 days)
Device success: a. Defined as complete versus incomplete PVL closure; b. For incomplete closure (i.e., residual PVL): grading of severity should be performed; and c. Appropriate recommendations for change in PVL severity, improvement in HF, or hemolysis should be determined by the specific patients being studied: i. For instance, when using a 5-class scheme, procedural success in patients with HF may be defined as less than or equal to mild (or < _ 1þ in 4-class) plus reduction of at least 1 class of PVL severity. 
Central Illustration

Relevant endpoints: primary and secondary
The PVLARC Writing Group uses terminology as per the 2014 AAC/AHA Key Data Elements and Definitions for Cardiovascular Events in Clinical Trials. 88 In 1988, the cardiovascular surgery societies pioneered the importance of standardized adverse event (AE) definitions in valve disease for adjudicating events in clinical trials, comparing clinical results of therapeutic interventions in valve disease, and standardizing reporting of events to facilitate data analysis. 89 More recently, the ARC has contributed guidelines for standardized definitions of AEs in several areas of interventional cardiology, including bleeding (Bleeding Academic Research Consortium [BARC]), 90 transcatheter aortic valve implantation (VARC-2) (3), and mitral valve repair and regurgitation (Mitral Valve Academic Research Consortium) (4).
Building on the previous VARC publications, PVLARC provides definitions to support standardized reporting of the AEs associated with both surgical and transcatheter treatment of PVL. Such standardization is important for clinical trials testing new interventions and for reporting the results of these interventions. An independent clinical events committee should prospectively define AEs and assess their relatedness to clinical trial interventions. The adjudication of events should not be limited to the acute procedure period (30 days), but also, when appropriate, longer periods (e.g., death months after a disabling stroke due to the procedure).
AE endpoints
Mortality Mortality for PVL procedures should be divided into all-cause and cardiovascular mortality. As with other ARC definitions, data on immediate procedural mortality and procedural mortality should also be gathered ( Table 5) . Immediate procedural mortality refers to intraprocedural events that result in immediate or consequent death<72 h after the procedure (3). Procedural mortality is all-cause mortality within 30 days or during the index hospitalization (if this is longer than 30 days). Reporting of mortality events is important in PVL closure, and should be reported after 30 days during the follow-up, and then annually for up to 5 years. Adjudication of mortality should be performed using a combination of clinical and other contexts at the time of the index procedure. When possible, national death registries and databases should be used to check for mortality in patients lost to follow-up.
Stroke
Imaging
Various multisociety consensus documents 89, 91, 92 have observed that new diffusion-weighted magnetic resonance imaging sequence abnormalities may be present after cardiovascular procedures; however, the clinical significance of those findings is unknown. Definitions relevant to neurological events are listed in Table 6 . Brain imaging is often performed for evaluation of stroke, typically using modalities such as CT for acute hemorrhage, as well as for acute, subacute, and chronic infarction. Magnetic resonance imaging is more sensitive for acute infarction, and can also identify chronic ischemia, as well as both acute and chronic hemorrhage. Imaging as a stand-alone entity should not be used to diagnose a stroke; the diagnosis should be made in conjunction with clinical assessment, preferably by a neurologist.
Primary endpoints
All strokes (ischemic and hemorrhagic) and transient ischemic attacks should be reported as endpoints, as defined in Table 6 .
Secondary endpoints
Functional outcome should be a secondary endpoint of the investigation.
The modified Rankin Scale is often used for this purpose. 93 Functional outcome should be assessed and documented by a certified provider at all scheduled visits in the trial, and at 90 days after stroke onset, as well as at the trial's end of follow-up. Disabling stroke is another secondary endpoint that is usually defined at 90 days from symptom onset ( Table 6) .
Management
If a potential neurological endpoint occurs, patients should be assessed by a neurologist as soon as possible, and brain imaging should be completed (magnetic resonance imaging or CT). In addition, baseline risk factors should be assessed and documented for patients to • Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dl or requiring transfusion of 2 or 3 U of whole blood/RBCs, or causing hospitalization or permanent injury, or requiring surgery and does not meet criteria of life-threatening or disabling bleeding Minor bleeding (BARC type 2 or 3a, depending on severity)
• Any bleeding worthy of clinical mention (e.g., access site hematoma) that does not qualify as life-threatening, disabling, or major BARC, Bleeding Academic Research Consortium; RBC, red blood cell.
identify the cause of the stroke. Strokes that occur after the procedure show the importance of investigating adjunctive pharmacotherapy after PVL closure. Medications and doses should be included. Acute stroke management strategies should also be recorded.
Bleeding complications
The standard BARC classification of bleeding complications remains applicable to PVL closure ( Table 7 ). An objective assessment is necessary, including risk stratification of bleeding events associated with mortality or chronic sequelae. Bleeding can be divided into lifethreatening bleeding, major bleeding, and minor bleeding. Transfusions should be recorded in case report forms.
Hemolysis
Although hemolysis may be commonly seen with mechanical prostheses, it rarely causes overt anemia or requires transfusions. 94, 95 Severe hemolytic anemia may require repetitive transfusions that would not be related to bleeding and/or hemorrhagic complication, as defined in the previous section. To standardize the reporting of endpoints in oncology/ hematology clinical trials, the National Cancer Institute has developed Common Terminology Criteria that could be applied to hemolytic anemia in the context of a cardiovascular intervention. In this context, the severity of anemia is reported by grade on a scale of 1 to 5, as described in Table 8 . The number and frequency of transfusions should be recorded. As noted previously, a comprehensive assessment of blood markers of hemolysis should be performed, including serum LDH, serum haptoglobin levels, antiglobulin antibodies, serum iron and folic acid levels, and peripheral blood smear examination for schistocytes.
Acute kidney injury
Small changes in kidney function can lead to acute kidney injury (AKI) and increased risk for mortality. 96 The Kidney Disease: Improving Global Outcomes system is a modification of the Acute Kidney Injury Network classification that allows for AKI diagnosis up to 7 days after the index procedure ( Table 9) . 97 AKI is defined as any of the following (not graded):
• Increase in serum creatinine by > _ 0.3 mg/dl (> _26.5 lmol/l) within 48 h; or
• Increase in serum creatinine to > _ 1.5Â baseline, which is known or presumed to have occurred within the prior 7 days; or
• Urine volume<0.5 ml/kg/h for 6 h. 
Vascular access-site and access-related complications
Major and minor access-site complications are inescapable, but major vascular complications are important clinical endpoints ( Table 10) . The access site includes any location (arterial or venous) traversed by a guidewire, catheter, or sheath (including the LV apex). Accessrelated is defined as any adverse clinical consequence associated with the access site. Vascular access can be a combination of femoral arterial or venous access, as well as LV apical access. Pre-planned surgical access or planned endovascular approach to vascular closure is part of the procedure, and is not a complication unless clinical complications are documented (e.g., bleeding, limb ischemia, distal embolization, or neurological impairment). Complications for all sites should be systematically recorded. All vascular complications should be recorded as either access-site related (e.g., femoral artery dissection) or non-access-site related (e.g., aortic dissection or rupture).
Complications that fulfill multiple criteria (vascular access site and major bleeding) should be listed under both headings.
Other PVL closure-related complications PVLARC recommends definitions for several other endpoints (Table 11) .
Surrogate imaging endpoints
The primary imaging endpoints should be 2D or 3D Doppler echocardiographic assessment of regurgitation severity and its consequences on LV mass, size, and function, as well as estimates of pulmonary artery pressure. Deformation characteristics of the LV have been studied in patients with native aortic regurgitation. 98 Myocardial strain and energy dissipation 99 might serve as more sensitive markers of the LV load imposed by the leakage, thus facilitating an earlier stratification of PVL patients and precluding the need to wait for negative remodeling to develop. These markers need to be evaluated.
Functional assessment
Multiple well-recognized prognostic indicators describe clinical and functional capacity, including: peak oxygen consumption, which is the standard measurement for assessment of exercise capacity; NYHA functional class, which is the standard grading system of functional status in the clinical setting; and the 6-min walk test, which is considered a realistic assessment of daily physical activity. 100 These and other functional parameters have been shown to be prognostic indicators in recent transcatheter aortic valve replacement trials, [101] [102] [103] and require further study in this population. Given the complex nature of this parameter, the investigation of new means of defining functional capacity, such as activity trackers, 104,105 may be useful in this patient population.
QOL endpoints
A comprehensive assessment of health-related QOL, which incorporates both an HF-specific measure (such as the Minnesota Living With Heart Failure 106 and the Kansas City Cardiomyopathy ), is important for patients undergoing PVL closure. Compared with the questionnaire-based scores (e.g., EuroQOL five dimensions questionnaire), self-rated assessments (e.g., EQ visual analogue score) tend to be lower at baseline and demonstrate greater improvement thereafter, 109 representing a potentially more sensitive marker of health status improvement after therapy. Notably, the attrition of the sickest patients with severe PVL might lead to a spurious improvement of QOL measurements over time. Therefore, a "poor outcome," defined as death or poor QOL, is always preferred to an isolated QOL score. 110 Until the data on the specific impact of PVL on health-related QOL become available, PVLARC recommends that an early (30 days) HF-specific assessment be combined with a generic self-rated visual analog, as well as death, in a comprehensive "poor outcome" parameter to rate the overall health status improvement.
Trial design in PVL
Innovative trial design for transcatheter closure devices should be contemplated to reduce sample size, costs, and operational burden, while maintaining a high degree of scientific validity. Before a trial can be properly designed, the PVL study group must be carefully defined, the clinical question to be addressed should be precisely identified, the device(s) should be selected, and clinical success should be defined. There are several possible trial designs, including comparing PVL reduction by transcatheter therapies to surgical correction in patients with moderate disease, or to medical therapy alone in patients unsuitable for surgery. Trial design for PVL closure is plagued by unsolved practical and ethical issues. For instance, because of the relative rarity of PVL, sample size is an important consideration. Additionally, a clinical trial of surgical versus percutaneous PVL intervention could be hindered by several factors, including cost, patient reluctance to be randomized (by definition all patients will have had prior thoracotomy), or inability to blind investigators or imaging core laboratories (percutaneous PVL technology has distinct imaging footprints). Furthermore, PVL surgery generally has poor outcomes, with substantial mortality and poor freedom from recurrence. We have a less-robust experience with clinical studies of transcatheter closure. The emergence of some evidence in favor of transcatheter closure of PVL may challenge the basis for clinical equipoise, and would raise questions about how best to design the randomization of vulnerable patients in a clinical trial where epistemic indifference might be lacking.
Nonetheless, these issues also open the door to innovative trial designs for prospective clinical investigation in rapidly evolving fields, such as PVL closure, where what is thought to be true at the start of a trial may no longer be accurate at its end. Because the use of different trial designs may be appropriate for any given study, a discussion of all trial designs is outside the scope of this document. Investigators should understand the rationale behind trial designs such as adaptive randomization, 111 Bayesian statistics, 112 and randomized registry trials. 113 
Conclusions
This consensus document is derived from multidisciplinary expertise, and represents a first step toward standardization of core principles and endpoint definitions in clinical studies of PVL treatment. Despite limitations to and unresolved questions concerning current trial design, the PVLARC committee recommends these standards for clinical PVL studies in surgical prostheses. 
